Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11741221 | 0.83 | LMNA (0.40) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL11738621 | 0.83 | ALDH1A1 (0.49) | MAPTALDH1A1SMN1; SMN2CTDSP1LMNA | |
| SCHEMBL1716245 | 0.81 | CES2 (0.46) | MAPTCES2ACHECES1ALDH1A1 | |
| SCHEMBL27816496 | 0.80 | LMNA (0.40) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL31016530 | 0.78 | L3MBTL1 (0.48) | MAPTCES2ACHECES1ALDH1A1 | |
| SCHEMBL13930332 | 0.78 | L3MBTL1 (0.48) | MAPTCES2ACHECES1ALDH1A1 | |
| SCHEMBL11742487 | 0.77 | MAPT (0.42) | MAPTCES2ACHECES1ALDH1A1 | |
| SCHEMBL22391943 | 0.76 | ALDH1A1 (0.47) | MAPTALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL16585208 | 0.76 | LMNA (0.44) | MAPTCES2ACHECES1ALDH1A1 | |
| SCHEMBL31016515 | 0.76 | LMNA (0.44) | MAPTCES2ACHECES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-1625129-B1 | HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT | BAYER HEALTHCARE AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| EP-1625129-A1 | HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT | Bayer HealthCare AG (DE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099212-A1 | HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | TYMP, RPL35, EIF2AK2 | MAPT 2799/4885CES2 1783/4885ACHE 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.